Infectologia

O que se sabe – e o que não se sabe – sobre a nova pílula da Merck para Covid-19.

8 Out, 2021 | 11:23h

What we know — and don’t know — about Merck’s new Covid-19 pill – STAT

Conteúdos relacionados:

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Opinião | Por que os americanos ainda – Ainda! – estão usando máscaras de tecido?

8 Out, 2021 | 11:21h

Why Are Americans Still—Still!—Wearing Cloth Masks? – The Atlantic

Conteúdos relacionados:

Evidence shows that, yes, masks prevent COVID-19 – and surgical masks are the way to go.

Face masks for COVID pass their largest test yet – “A rigorous study finds that surgical masks are highly protective, but cloth masks fall short”.

[Preprint] Largest study of masks yet details their importance in fighting Covid-19.

Comentário no Twitter

Any mask is better than no mask, especially indoors. But for those who are at higher risk of severe disease or around lots of unvaccinated people, consider upgrading to an N95 (or equivalent) mask, which are more protective. https://t.co/vhNPadTP8O

— Dr. Tom Frieden (@DrTomFrieden) October 5, 2021

Suplemento | Triunfos da vacinação.

8 Out, 2021 | 11:05h

Página principal: Triumphs of Vaccination – The Journal of Infectious Diseases

Triumphs of Immunization

Pertussis (Whooping Cough)

Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease

The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease

Hepatitis B Vaccines

Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe

Rubella Eradication: Not Yet Accomplished, but Entirely Feasible

Human Papillomavirus Vaccines

Smallpox

Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster

Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication

Influenza Vaccines: Successes and Continuing Challenges

Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination

Herpes Zoster Vaccines

Overview of the United States’ Immunization Program

The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade

Revisão sistemática | Pretomanida para tuberculose.

8 Out, 2021 | 10:59h

Pretomanid for tuberculosis: a systematic review – Clinical Microbiology and Infection

Conteúdos relacionados:

Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.

WHO announces updates on new molecular assays for the diagnosis of tuberculosis (TB) and drug resistance

WHO announces updated definitions of extensively drug-resistant tuberculosis

Estudo de coorte | Efetividade da vacina da Pfizer contra qualquer infecção caiu de 88% no 1º mês após a vacinação completa para 47% após 5 meses. A efetividade da vacina contra internações permaneceu alta: 87% em 1 mês e 88% depois de 5 meses da vacinação completa, sem declínio significativo.

5 Out, 2021 | 11:36h

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study – The Lancet

Comentário: Expert reaction to study on Pfizer-BioNTech vaccine effectiveness up to 6 months – Science Media Centre

Comentário no Twitter

Study of 3.4 million people @aboutKP @TheLancet

Vaccine efficacy against infections:
– First month post: 88%
– 5 months post: 47%

But vaccine efficacy against hospitalization (Figure):
– First month post: 87%
– 5 months post: 88 %https://t.co/1Gse0FKpoI pic.twitter.com/p9wyiaWGeg

— Vincent Rajkumar (@VincentRK) October 4, 2021

Estudo de coorte | Miocardite aguda após vacina de mRNA contra COVID-19 em maiores de 18 anos é rara, e a maioria dos casos não é grave.

5 Out, 2021 | 11:34h

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older – JAMA Internal Medicine

Editorial: COVID-19 Messenger RNA Vaccination and Myocarditis—A Rare and Mostly Mild Adverse Effect

Comentário no Twitter

New report on very rare acute myocarditis after mRNA vaccination in age 18+
5.8 cases/million after 2nd dose, 0.8/million 1st dose, all cases fully resolved with conservative managementhttps://t.co/Mfh5ImiSpW @KPSCALnews @KPSCalResearch @JAMAInternalMed

— Eric Topol (@EricTopol) October 4, 2021